Compounds > selegiline
Page last updated: 2024-08-23

selegiline and baclofen

selegiline has been researched along with baclofen in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Hollán, S; Magyar, K; Vécsei, L1

Reviews

1 review(s) available for selegiline and baclofen

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for selegiline and baclofen

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Adverse effects of dopamine potentiation by long-term treatment with selegiline.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anemia, Hemolytic, Congenital; Antiparkinson Agents; Baclofen; Basal Ganglia; Basal Ganglia Diseases; Blood Platelets; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Female; Genetic Carrier Screening; Genotype; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Huntingtin Protein; Long-Term Care; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Neurologic Examination; Neuroprotective Agents; Nuclear Proteins; Polymerase Chain Reaction; Proteins; Psychoses, Substance-Induced; Reference Values; Selegiline; Trinucleotide Repeats

2004